Empowering patients, elevating pharma brands

Thanks to Temedica’s health insights, we gain a profound and precise understanding of care realities and patient journeys of individual patient cohorts. This knowledge enables us to plan our initiatives with greater precision and to focus even more on the individual needs of patients.

Temedica's Permea Disease Navigator and Services confirmed our initial assumptions and revealed new insights into co-medications, co-morbidities, and regional diagnostics, enhancing our region-specific strategy development.

I am impressed with Temedica's analytical capabilities. By incorporating its many insights and perspectives into our decision-making processes, we have achieved a significant transformation. We gain comprehensive insights into trends, behaviors, and specific needs related to women's health, enabling us to make informed business decisions.

The expansive data landscape of the Temedica ecosystem is a treasure trove for scientists to produce actionable insights for clinical practice.

Based on my experience in Real-World Evidence research, I like Temedica's innovative approach to facilitate a prompt, comprehensive, and precise understanding of patient journeys, disease burden, and health outcomes, particularly in the field of multiple sclerosis. 

As a collaboration partner with Temedica, we are excited about their novel insights. These have the potential to take today's approach to medicine to a new level - for example, by combining real-world insights from digital tools with various other intelligent sources of information to sustainably improve patient care.

The Brisa Patient Companion has opened new doors in how we interact with and understand MS patients. Its ability to provide real-time, actionable insights serves as a bridge, connecting patient experiences with our care strategies, leading to more personalized and effective treatments.

The Permea Disease Navigator shed light on crucial insights we didn’t even realize we were missing. It’s changing the trajectory of our efforts in product development and marketing.

Temedica's extensive ecosystem, rich with real-world insights, proves indispensable in my work on 'digital twins.' This allows for personalized diagnoses and a deeper understanding of disease phenotypes. Together with Temedica, we're transitioning to concise, data-driven narratives, thereby promoting patient understanding and transparency.